Germany
Japan
United Kingdom
China
Antibodies
USD 390.00
In Stock
MHC Class I Heavy Chain (Restricted expression) mouse monoclonal antibody, clone HC10, Purified
| Applications | ELISA, EM, FC, IF, IHC, IP, WB |
| Reactivities | Human |
Fibroblasts (Pan Reticular) rat monoclonal antibody, clone ER-TR7, Purified
| Applications | FC, IF, IHC |
| Reactivities | Human, Mouse |
H2-D1 mouse monoclonal antibody, clone 28-14-8, Purified
| Applications | CT, FC, FN, IHC, IP |
| Reactivities | Mouse |
ICAM1 mouse monoclonal antibody, clone MEM-111, Purified
| Applications | ELISA, FC, IHC, WB |
| Reactivities | Bovine, Human, Rat |
USD 475.00
2 Weeks
Cd28 hamster monoclonal antibody, clone 37.51, Purified
| Applications | FC, FN, IP |
| Reactivities | Mouse |
CD1.1 mouse monoclonal antibody, clone 76-7-4, FITC
| Applications | FC |
| Reactivities | Porcine |
| Conjugation | FITC |
Anti-LGR5 mouse mAb, clone OTI2A2, DyLight 488 conjugated
| Applications | FC |
| Reactivities | Human, Mouse |
| Conjugation | DyLight 488 |
HLA Class I ABC mouse monoclonal antibody, clone W6/32, FITC
| Applications | FC |
| Reactivities | Bovine, Feline, Human, Primate |
| Conjugation | FITC |
CD8A mouse monoclonal antibody, clone MEM-31, PerCP
| Applications | FC |
| Reactivities | Human |
| Conjugation | PerCP |
HLA Class II DR mouse monoclonal antibody, clone L243, Purified
| Applications | FC, FN, IF, IHC, IP, WB |
| Reactivities | Canine, Human, Primate |
USD 220.00
2 Weeks
p75 NGF Receptor (NGFR) (1-160) mouse monoclonal antibody, clone NGFR5, Purified
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Feline, Ferret, Human, Monkey, Rabbit |
Lyve1 rabbit polyclonal antibody, Purified
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Mouse, Rat |
| Immunogen | Highly pure recombinant Mouse soluble LYVE-1 (Ala24-Gly228) produced in insect cells (Cat.-No DA3524). This recombinant soluble LYVE-1 consists of amino acid 24 (Ala) to 228 (Gly) and is fused to a C-terminal His-tag (6xHis). |
p21 (CDKN1A) mouse monoclonal antibody, clone WA-1, Purified
| Applications | FC, IF, IHC |
| Reactivities | Chimpanzee, Human, Monkey, Mouse, Rat |
CD4 mouse monoclonal antibody, clone MEM-115, Azide Free
| Applications | FC, FN, IP, WB |
| Reactivities | Human |
Cd80 hamster monoclonal antibody, clone 16-10A1, Aff - Purified
| Applications | FC, FN, IHC, IP |
| Reactivities | Canine, Mouse |
USD 390.00
2 Weeks
MHC Class I Heavy Chain (Restricted expression) mouse monoclonal antibody, clone HCA2, Purified
| Applications | ELISA, FC, IF, IHC, IP, WB |
| Reactivities | Human |
p21 (CDKN1A) mouse monoclonal antibody, clone WA-1, Purified
| Applications | FC, IF, IHC |
| Reactivities | Chimpanzee, Human, Monkey, Mouse, Rat |
Collagen I (COL1A1) rabbit polyclonal antibody, Biotin
| Applications | ELISA, FC, IHC, IP, WB |
| Reactivities | Bovine, Human, Mammalian, Mouse, Rat |
| Conjugation | Biotin |
| Immunogen | Collagen Type I from Human and Bovine placenta. |
Rabbit Polyclonal PD-L1 Antibody
| Applications | FC, IF, IHC, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Immunogen | PD-L1 antibody was raised against a 17 amino acid synthetic peptide from near the center of human PD-L1. The immunogen is located within amino acids 60 - 110 of PD-L1. |
EPCAM mouse monoclonal antibody, clone 323/A3, Aff - Purified
| Applications | FC, IF, IHC, IP, WB |
| Reactivities | Human |
CD3E mouse monoclonal antibody, clone MEM-92, Purified
| Applications | FC, FN, IP |
| Reactivities | Human |
LYVE1 rabbit polyclonal antibody, Aff - Purified
| Applications | ELISA, FC, IF, IHC, WB |
| Reactivities | Human |
| Immunogen | Highly pure recombinant Human soluble LYVE-1 produced in insect cells (Cat.-No DA3525). It consists of amino acid 24 (Ser) to 232 (Gly) and is fused to a C-terminal His-tag (6xHis). |
CD82 mouse monoclonal antibody, clone C33, Aff - Purified
| Applications | FC, FN, IF, IHC, IP, WB |
| Reactivities | Human |
Glycophorin A (GYPA) (N-term) mouse monoclonal antibody, clone HIR2, Purified
| Applications | AGG, FC, IHC |
| Reactivities | Human |
Active filters
Category
-
Antibodies
- Primary Antibodies
Applications
- FC
Filter by
Target Symbol
- PDCD1 (209)
- CD5 (194)
- HAVCR2 (123)
- CTAG1B (116)
- ERCC1 (115)
- LIPG (105)
- PECAM1 (98)
- CD274 (95)
- L1CAM (87)
- CD47 (85)
- CTNNB1 (84)
- ERBB2 (83)
- PTPRC (81)
- TP53 (81)
- PDCD1LG2 (80)
- CTLA4 (79)
- TNFRSF8 (79)
- CD8A (78)
- CD99 (75)
- CD33 (72)
- CD40 (71)
- TIGIT (70)
- ICOS (68)
- FGF21 (65)
- LRATD2 (65)
- PNMT (65)
- SENP2 (65)
- CD86 (63)
- LGR5 (63)
- CD80 (59)
- LAG3 (59)
- TNFRSF9 (59)
- AFP (57)
- SQSTM1 (56)
- ACAT2 (55)
- CD63 (55)
- MICAL1 (55)
- RNF144B (55)
- TTC32 (55)
- TTLL12 (55)
- UBE2E3 (55)
- ZFP36 (55)
- CD2 (54)
- BTLA (52)
- IGF2BP2 (51)
- CDK2 (50)
- HIBCH (50)
- KATNB1 (50)
- LENG1 (50)
- MAPK7 (50)
- MAPRE2 (50)
- MEIS3 (50)
- MOB3B (50)
- NME4 (50)
- NPR3 (50)
- PACSIN3 (50)
- PDE4A (50)
- PFKP (50)
- PRKCE (50)
- RPN1 (50)
- SDR9C7 (50)
- SMS (50)
- TACC3 (50)
- BTK (49)
- CD19 (47)
- CD27 (47)
- CD38 (46)
- DSTN (46)
- IL2RA (46)
- SNX9 (46)
- ACY1 (45)
- AK5 (45)
- ARHGAP25 (45)
- BECN1 (45)
- BTN1A1 (45)
- CBWD1 (45)
- CD4 (45)
- EPM2AIP1 (45)
- EXD1 (45)
- GSTT2 (45)
- HOXC11 (45)
- LDLRAP1 (45)
- LIMK1 (45)
- LRRC25 (45)
- NRBP1 (45)
- NT5DC1 (45)
- PDE2A (45)
- PIK3AP1 (45)
- SIRT5 (45)
- SNAP25 (45)
- SRR (45)
- STAT5A (45)
- TAL1 (45)
- TUBAL3 (45)
- CD3E (43)
- NGFR (42)
- AKT1 (41)
- ATP5F1B (41)
- FSHB (41)
- GPHN (41)
Reactivities
- Human (17874)
- Mouse (10142)
- Rat (9397)
- Monkey (2140)
- Dog (1648)
- Bovine (70)
- Canine (42)
- Pig (36)
- Chicken (32)
- Rabbit (27)
- Porcine (25)
- Primate (25)
- Sheep (19)
- Escherichia coli (17)
- Xenopus (15)
- Hamster (13)
- Chimpanzee (12)
- Cow (10)
- Zebrafish (7)
- Goat (6)
- Baboon (5)
- SARS-CoV-2 (5)
- Cynomolgus (4)
- Drosophila (4)
- Feline (4)
- Rhesus Monkey (4)
- C. elegans (2)
- Dengue virus (2)
- Ferret (2)
- Fish (2)
- Macaque (2)
- Marmoset (2)
- West Nile Virus (2)
- Yellow Fever Virus (2)
- Equine (1)
- Guinea Pig (1)
- Mustelid (1)
- Squirrel (1)
- Staphylococcus aureus (1)
- Yeast (1)
Antibody Hosts
Isotypes
- IgG1 (14033)
- IgG2a (4336)
- IgG2b (3167)
- IgG (856)
- Ig (819)
- IgG, kappa (231)
- IgG1, kappa (196)
- IgM (190)
- IgG3 (114)
- IgG2a, kappa (82)
- IgG2b, kappa (39)
- IgG1, lambda (22)
- IgG2c (22)
- IgG2 (8)
- Fab fragment, kappa (7)
- IgA (7)
- IgG2a, lambda (6)
- IgM, kappa (5)
- IgG4 (4)
- IgG3, kappa (3)
- Fab fragment, lambda (2)
- IgG2b, lambda (2)
- scFv (2)
- cocktail (1)
Clonalities
Conjugates
- Unconjugated (11577)
- Biotin (3697)
- HRP (3259)
- FITC (909)
- PE (756)
- APC (159)
- Alexa Fluor 488 (55)
- Alexa Fluor 647 (51)
- PerCP (34)
- Alexa Fluor 546 (17)
- Texas Red (13)
- PE-Cy7 (11)
- His Tag (9)
- APC-Cy7 (7)
- Cy5 (7)
- DyLight 488 (6)
- PE-Cy5.5 (6)
- TRITC (6)
- PE-DL594 (4)
- PE-TXRD (4)
- APC-Cy5.5 (3)
- PerCP-Cy5.5 (3)
- FLMA (2)
- Rhodamine (2)
- BIMA (1)
- DTAF (1)
- DyLight 633 (1)
- PE-Cy5 (1)
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (55)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (34)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (18)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (17)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (16)
- This is a chimeric antibody created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (14)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (13)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (12)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (10)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (9)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (6)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG2 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- Phospho-specific (2)
- This chimeric hamster (Armenian) antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (2)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Armenian Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric antibody created to reduce immunogenicity during in vivo applications. (1)
- This is a chimeric mouse antibody, based on the original hamster IgG format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric recombinant Fab fragment created as part of a panel offering antibodies of the same specificity in different formats (species, isotype, subtype and modified versions) for use as isotype controls. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This reformatted antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Families
- Druggable Genome (11102)
- Transmembrane (5122)
- Transcription Factors (1724)
- ES Cell Differentiation/IPS (1606)
- Secreted Protein (1335)
- Protease (950)
- Protein Kinase (909)
- Stem cell - Pluripotency (682)
- Adult stem cells (377)
- Phosphatase (325)
- Embryonic stem cells (203)
- P450 (160)
- GPCR (147)
- Ion Channels: Other (125)
- Stem cell relevant signaling - JAK/STAT signaling pathway (107)
- Cancer stem cells (105)
- Stem cell relevant signaling - DSL/Notch pathway (105)
- Induced pluripotent stem cells (77)
- Nuclear Hormone Receptor (47)
- Ion Channels: Potassium (34)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (26)
- Stem cell relevant signaling - Wnt Signaling pathway (14)
- Ion Channels: Cys-loop Receptors (4)
- Ion Channels: Sodium (2)
- Ion Channels: ATP Receptors (1)
- Ion Channels: Glutamate Receptors (1)
Pathways
- Metabolic pathways (2316)
- Cell adhesion molecules (CAMs) (1357)
- Pathways in cancer (934)
- Hematopoietic cell lineage (826)
- T cell receptor signaling pathway (717)
- Cytokine-cytokine receptor interaction (655)
- MAPK signaling pathway (616)
- Prostate cancer (474)
- Purine metabolism (462)
- Focal adhesion (441)
- Leukocyte transendothelial migration (436)
- Primary immunodeficiency (421)
- Progesterone-mediated oocyte maturation (409)
- Regulation of actin cytoskeleton (397)
- Toll-like receptor signaling pathway (389)
- Endometrial cancer (380)
- Cell cycle (376)
- Neurotrophin signaling pathway (375)
- Colorectal cancer (367)
- Chronic myeloid leukemia (354)
- Jak-STAT signaling pathway (350)
- Huntington's disease (346)
- Pancreatic cancer (346)
- Fc gamma R-mediated phagocytosis (341)
- Systemic lupus erythematosus (339)
- Apoptosis (336)
- Non-small cell lung cancer (333)
- Insulin signaling pathway (329)
- Melanoma (329)
- Adherens junction (320)
- Endocytosis (320)
- ErbB signaling pathway (317)
- Alzheimer's disease (316)
- Wnt signaling pathway (299)
- Bladder cancer (297)
- Autoimmune thyroid disease (290)
- B cell receptor signaling pathway (288)
- Glycolysis / Gluconeogenesis (287)
- Pathogenic Escherichia coli infection (276)
- Small cell lung cancer (274)
- Ubiquitin mediated proteolysis (269)
- Tight junction (263)
- Glioma (258)
- Allograft rejection (244)
- Viral myocarditis (240)
- Pyruvate metabolism (234)
- Fc epsilon RI signaling pathway (232)
- Natural killer cell mediated cytotoxicity (231)
- p53 signaling pathway (230)
- Thyroid cancer (228)
- Acute myeloid leukemia (224)
- Axon guidance (224)
- Arginine and proline metabolism (223)
- Nucleotide excision repair (222)
- Gap junction (215)
- Glycerolipid metabolism (215)
- Parkinson's disease (202)
- Adipocytokine signaling pathway (200)
- Valine (199)
- Drug metabolism - cytochrome P450 (197)
- Oxidative phosphorylation (196)
- leucine and isoleucine degradation (187)
- Metabolism of xenobiotics by cytochrome P450 (184)
- Oocyte meiosis (184)
- Fructose and mannose metabolism (179)
- Type I diabetes mellitus (179)
- Graft-versus-host disease (178)
- ECM-receptor interaction (175)
- Calcium signaling pathway (174)
- Basal cell carcinoma (171)
- Type II diabetes mellitus (171)
- Chemokine signaling pathway (170)
- Tyrosine metabolism (169)
- Renal cell carcinoma (167)
- Antigen processing and presentation (164)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (163)
- Pyrimidine metabolism (156)
- GnRH signaling pathway (153)
- Proteasome (153)
- Amyotrophic lateral sclerosis (ALS) (151)
- Glycine (149)
- serine and threonine metabolism (149)
- Glutathione metabolism (148)
- mTOR signaling pathway (139)
- Complement and coagulation cascades (137)
- TGF-beta signaling pathway (136)
- Propanoate metabolism (130)
- Melanogenesis (128)
- Retinol metabolism (127)
- Tryptophan metabolism (126)
- VEGF signaling pathway (122)
- Cysteine and methionine metabolism (116)
- beta-Alanine metabolism (116)
- Fatty acid metabolism (115)
- Histidine metabolism (115)
- Arachidonic acid metabolism (110)
- Vascular smooth muscle contraction (110)
- Lysosome (109)
- Neuroactive ligand-receptor interaction (108)
- Pentose phosphate pathway (105)
- Butanoate metabolism (99)
- Renin-angiotensin system (99)
- Epithelial cell signaling in Helicobacter pylori infection (98)
- Asthma (95)
- Regulation of autophagy (93)
- NOD-like receptor signaling pathway (90)
- Nicotinate and nicotinamide metabolism (88)
- Citrate cycle (TCA cycle) (85)
- Lysine degradation (85)
- PPAR signaling pathway (83)
- Hypertrophic cardiomyopathy (HCM) (82)
- Terpenoid backbone biosynthesis (82)
- Glyoxylate and dicarboxylate metabolism (78)
- Dilated cardiomyopathy (77)
- Starch and sucrose metabolism (76)
- Amino sugar and nucleotide sugar metabolism (75)
- Linoleic acid metabolism (73)
- RIG-I-like receptor signaling pathway (72)
- Porphyrin and chlorophyll metabolism (70)
- Synthesis and degradation of ketone bodies (70)
- Long-term depression (69)
- Alanine (67)
- aspartate and glutamate metabolism (67)
- Prion diseases (65)
- DNA replication (64)
- Mismatch repair (64)
- Cardiac muscle contraction (62)
- Galactose metabolism (62)
- Notch signaling pathway (60)
- RNA degradation (60)
- N-Glycan biosynthesis (59)
- Vibrio cholerae infection (58)
- Cytosolic DNA-sensing pathway (57)
- Caffeine metabolism (56)
- Inositol phosphate metabolism (55)
- Androgen and estrogen metabolism (50)
- Long-term potentiation (50)
- Ascorbate and aldarate metabolism (47)
- Maturity onset diabetes of the young (47)
- SNARE interactions in vesicular transport (47)
- One carbon pool by folate (46)
- Drug metabolism - other enzymes (44)
- Non-homologous end-joining (43)
- Spliceosome (41)
- Folate biosynthesis (37)
- Homologous recombination (37)
- Selenoamino acid metabolism (37)
- Phosphatidylinositol signaling system (36)
- Cyanoamino acid metabolism (35)
- Sulfur metabolism (35)
- Base excision repair (33)
- Pantothenate and CoA biosynthesis (32)
- Phenylalanine metabolism (26)
- Aminoacyl-tRNA biosynthesis (25)
- Olfactory transduction (25)
- Biosynthesis of unsaturated fatty acids (24)
- Glycerophospholipid metabolism (24)
- ABC transporters (23)
- Basal transcription factors (23)
- Glycosaminoglycan degradation (23)
- Dorso-ventral axis formation (22)
- RNA polymerase (22)
- Nitrogen metabolism (20)
- Riboflavin metabolism (20)
- Vitamin B6 metabolism (20)
- Methane metabolism (18)
- Hedgehog signaling pathway (17)
- Circadian rhythm - mammal (15)
- Thiamine metabolism (15)
- Sphingolipid metabolism (14)
- Limonene and pinene degradation (13)
- Other glycan degradation (13)
- Pentose and glucuronate interconversions (12)
- leucine and isoleucine biosynthesis (12)
- Glycosphingolipid biosynthesis - lacto and neolacto series (8)
- Steroid biosynthesis (7)
- C21-Steroid hormone metabolism (6)
- Keratan sulfate biosynthesis (6)
- Biotin metabolism (5)
- Glycosphingolipid biosynthesis - ganglio series (5)
- O-Glycan biosynthesis (5)
- Ribosome (5)
- Taste transduction (5)
- Ether lipid metabolism (4)
- alpha-Linolenic acid metabolism (4)
- Heparan sulfate biosynthesis (3)
- Primary bile acid biosynthesis (3)
- Fatty acid biosynthesis (2)
- Fatty acid elongation in mitochondria (2)
- Phenylalanine (2)
- tyrosine and tryptophan biosynthesis (2)
- Chondroitin sulfate biosynthesis (1)
- D-Glutamine and D-glutamate metabolism (1)
- Glycosylphosphatidylinositol(GPI)-anchor biosynthesis (1)
- Lysine biosynthesis (1)
- O-Mannosyl glycan biosynthesis (1)
- Protein export (1)
- Taurine and hypotaurine metabolism (1)
- Ubiquinone and other terpenoid-quinone biosynthesis (1)